Tag: Clinical trials

Search News
Categories
Archives
Results from the Phase I STARPAC trial

24th September 2020

A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.

Read more

Immunotherapy for advanced bladder cancer

18th September 2020

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.

Read more

Investigating new treatment options for mesothelioma

16th September 2020

Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.

Read more

Proposed new surgery protocol for ovarian cancer

17th August 2020

For women at high risk of ovarian cancer, standard preventive practice is to offer removal of both the fallopian tubes and ovaries, but the surgery induces menopause in women who have not yet reached this stage of life. A proposed alternative two step surgical protocol, which delays the induced menopause caused by the removal of the ovaries, is highly acceptable to this premenopausal group of women.

Read more

Immunotherapy for advanced bladder cancer

29th May 2020

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.

Read more

Immune therapy reduces risk of recurrence in aggressive breast cancer

27th February 2020

An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.

Read more

Search News
Categories
Archives